Skip to main content
Premium Trial:

Request an Annual Quote

Silico Insights to Offer Comprehensive Bioinformatics Platform by Midsummer


Silico Insights, a bioinformatics tools provider based in Woburn, Mass., has developed a set of proprietary algorithms to establish patterns in gene expression and proteomics data that could be extended to cover the entire drug development pipeline, said Christos Hatzis, vice president of technology.

“Today’s bioinformatics portfolio is inadequate to meet the complex needs of post-genomic research,” said Hatzis. He said that the company’s algorithms would help enable a better understanding of the pathways and networks between genes, proteins, and drugs.

Silico Insights expects to begin deploying i-Sight, a platform based on the algorithms, before July.

“We’re backwards integrating into discovery to link proteomics and clinical data,” Hatzis told BioInform. “It’s the first step to getting to practical functional genomics.”

The i-Sight platform includes a pre-processing data normalization step and then applies an array of clustering techniques and predictive algorithms to analyze gene expression and proteomics profiles. The algorithms evaluate patterns using time-shifted correlation analysis and rank gene expression-proteomic associations based on the correlations. An interactive user interface provides pre-defined templates for analysis and enables users to drill through for data extraction and data links.

Hatzis said that i-Sight is unique in its capability to create associations between genomic and proteomic data.

“Platforms in use today place a strong emphasis on data integration and add a few analytical tools to interpret the integrated data. Our platform specializes in analytical capabilities to derive complete understanding of disparate data and could complement existing platforms that enable data warehousing of discovery data,” Hatzis said.

Hatzis said that i-Sight currently addresses clinical and post-approval drug safety data, with genomic and proteomics data analysis capabilities to follow soon behind. He said that a pharmacogenomics piece would be added in another six months.

A patent is pending on the technology.

— BT

Filed under

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.